ALSO NOTED: Memory raises $31 million; Myriad Genetics says Flurizan stabilizes Alzheimer's patients; Barrier retains Hyphanox

> Memory Pharmaceutical raises $31 million in private stock sale. Release

> Myriad Genetics says that a follow-on analysis of a mid-stage trial of Flurizan appeared to stabilize the symptoms of Alzheimer's. Release

> Barrier Therapeutics of Princeton, N.J. says it will retain the worldwide rights to Hyphanox after Janssen notified the company that it would not exercise options on the drug. Hyphanox recently failed to hit the primary endpoint in a Phase III trial. Release

> CytRx has begun recruiting for a Phase II trial of a new drug for ALS. Report

And finally...Three Chicago children died from a staph germ they caught in the community, raising fears of the steady spread of the superbug. Feature